4568.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 11:45):

Stats
आज की मात्रा	5.32M
औसत मात्रा	4.34M
बाजार मूल्य	10 550.08B
EPS	¥0 ( 2024-04-24 )
अगली कमाई की तारीख	( ¥7.56 ) 2024-06-17
Last Dividend	¥15.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	52.63
ATR14	¥3.68 (0.07%)

मात्रा सहसंबंध

लंबा: 0.22 (neutral)

छोटा: -0.55 (weak negative)

Signal:(42.089) Neutral

Daiichi Sankyo Company, सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Daiichi Sankyo Company, सहसंबंध - मुद्रा/वस्त्र

0.38
( neutral )

0.27
( neutral )

0.45
( neutral )

0.14
( neutral )

-0.44
( neutral )

-0.61
( weak negative )

Daiichi Sankyo Company, वित्तीय

Annual	2023
राजस्व:	¥1 601.69B
सकल लाभ:	¥1 186.37B (74.07 %)
EPS:	¥104.69

FY	2023
राजस्व:	¥1 601.69B
सकल लाभ:	¥1 186.37B (74.07 %)
EPS:	¥104.69

FY	2022
राजस्व:	¥1 278.48B
सकल लाभ:	¥914.95B (71.57 %)
EPS:	¥56.96

FY	2022
राजस्व:	¥1 044.89B
सकल लाभ:	¥691.56B (66.19 %)
EPS:	¥34.94

Financial Reports:

No articles found.

Daiichi Sankyo Company, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥15.00 (N/A)	¥0 (N/A)	¥15.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Daiichi Sankyo Company, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.79 - Stable (4.18%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.08	2000-03-28
Last Dividend	¥15.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥443.25	--
Avg. Dividend % Per Year	0.00%	--
Score	4.04	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.79
Div. Directional Score	8.60	--

Next Divdend (Est)
(2024-08-05)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

4.04

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3156.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2121.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9010.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
8584.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7908.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7065.T	Ex Dividend Junior	2023-08-30	Annually	0.00%
6373.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
5301.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4350.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3526.T	Ex Dividend Junior	2024-03-28	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.125	1.500	7.49	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0580	1.200	8.07	9.68	[0 - 0.3]
returnOnEquityTTM	0.125	1.500	9.72	10.00	[0.1 - 1]
payoutRatioTTM	0.335	-1.000	6.65	-6.65	[0 - 1]
currentRatioTTM	3.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.522	0.800	5.75	4.60	[0.8 - 2.5]
cashRatioTTM	0.895	1.500	6.14	9.21	[0.2 - 2]
debtRatioTTM	0.0294	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	11.63	1.000	6.80	6.80	[3 - 30]
operatingCashFlowPerShareTTM	312.59	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	248.54	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0603	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.741	1.000	0.988	0.988	[0.2 - 0.8]
operatingProfitMarginTTM	0.132	1.000	9.36	9.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.89	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.463	0.800	-0.248	-0.199	[0.5 - 2]
Total Score				12.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	52.55	1.000	4.79	0	[1 - 100]
returnOnEquityTTM	0.125	2.50	9.82	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	248.54	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.909	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	312.59	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.335	1.500	6.65	-6.65	[0 - 1]
pegRatioTTM	-4.87	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.374	1.000	3.15	0	[0.1 - 0.5]
Total Score				4.79

Daiichi Sankyo Company,

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.